Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis
- PMID: 8121569
- DOI: 10.1097/00006123-199401000-00008
Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis
Abstract
In the vast majority of studies that address the role of surgery in the management of high-grade gliomas, the degree of tumor removal accomplished is solely based on the intraoperative perception of the neurosurgeon. Despite its fundamental importance for a comparison of different treatment modalities, little systematic effort has been made to evaluate the residual gross tumor by neuroimaging methods immediately after surgery. We report the results of a prospective study using contrast-enhanced computed tomography and magnetic resonance imaging (MRI) to monitor 60 patients after the resection of a high-grade glioma. In each case, the first scans were obtained between Days 1 and 5 after surgery, followed by serial imaging every 2 to 3 months, usually until the condition of the patient deteriorated severely or the patient died. Gadolinium-enhanced MRI proved to be extremely valuable for assessing gross residual tumor when performed during Days 1 to 3 after the resection of a preoperatively enhancing high-grade glioma. This timing avoided surgically induced contrast enhancement and minimized interpretative difficulties. In delineating residual tumor, MRI was vastly superior to computed tomography. About 80% of tumor "recurrences" emerged from definitely enhancing remnants, as revealed by early postoperative MRI. The neurosurgeon's estimation of gross tumor burden reduction could be shown to be much less accurate (by a factor of 3) than the postoperative assessment by modern neuroimaging. In our series, residual tumor enhancement was the most predictive prognostic factor of survival in patients with glioblastoma, followed by radiotherapy. Patients with a residual tumor postoperatively had a 6.595-times higher risk of death in comparison to patients without a residual tumor. Patients undergoing radiotherapy had a 0.258-times lower risk of death in comparison to patients who were not treated with radiation. Concerning survival, the prognostic significance of both variables surpassed age and performance.
Comment in
-
Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and influence on regrowth and prognosis.Neurosurgery. 1994 Jun;34(6):1105. doi: 10.1227/00006123-199406000-00039. Neurosurgery. 1994. PMID: 8084402 No abstract available.
Similar articles
-
Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis.Neurosurgery. 1995 Apr;36(4):872-4. doi: 10.1227/00006123-199504000-00044. Neurosurgery. 1995. PMID: 7596523 No abstract available.
-
Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107. doi: 10.1016/s0720-048x(02)00027-x. Eur J Radiol. 2003. PMID: 12536087
-
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.Radiother Oncol. 2011 May;99(2):218-24. doi: 10.1016/j.radonc.2011.03.006. Epub 2011 Apr 16. Radiother Oncol. 2011. PMID: 21497925
-
Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature.Childs Nerv Syst. 1997 Jan;13(1):17-23. doi: 10.1007/s003810050033. Childs Nerv Syst. 1997. PMID: 9083697 Review.
-
Reoperation for glioma.Clin Neurosurg. 1992;39:172-86. Clin Neurosurg. 1992. PMID: 1333931 Review. No abstract available.
Cited by
-
Extent of resection in malignant gliomas: a critical summary.J Neurooncol. 1999 May;42(3):303-5. doi: 10.1023/a:1006167412835. J Neurooncol. 1999. PMID: 10433112 No abstract available.
-
Operative treatment of subcortical metastatic tumours in the central region.J Neurooncol. 2011 Jul;103(3):567-73. doi: 10.1007/s11060-010-0420-5. Epub 2010 Sep 29. J Neurooncol. 2011. PMID: 20878448
-
Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients.J Neurooncol. 2000 Sep;49(2):147-55. doi: 10.1023/a:1026533016912. J Neurooncol. 2000. PMID: 11206010 Clinical Trial.
-
Current approaches to the management of brain metastases.Nat Rev Clin Oncol. 2020 May;17(5):279-299. doi: 10.1038/s41571-019-0320-3. Epub 2020 Feb 20. Nat Rev Clin Oncol. 2020. PMID: 32080373 Review.
-
Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement.Sci Rep. 2021 Oct 21;11(1):20828. doi: 10.1038/s41598-021-00193-x. Sci Rep. 2021. PMID: 34675225 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical